NEWS AND UPDATES
July 2024
Dr Henry Lee discussed the key elements of developing gene therapies for inherited disorders of neurotransmission including SSADH deficiency in a podcast at JIMD.
May 2024
Dr Henry Lee presents our work on SSADH deficiency in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
Galibra Neuroscience obtains Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene supplement therapy for SLC6A1-related disorders.
April 2024
Dr Guangping Gao joins Galibra Neuroscience as AAV Manufacturing Consultant.
Brad Hoffman joins Galibra Neuroscience as Director of Business Development.
January 2024
Galibra Neuroscience received its first funding support from an angel investor.
December 2023
Our work on SSADH deficiency was featured in a poster highlight session in the American Epilepsy Society Annual Meeting.
Amber Freed joins Galibra Neuroscience as Chief Development Officer.
Galibra Neuroscience obtains Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene replacement therapy for SSADH deficiency.
Dr Phillip Pearl joins Galibra Neuroscience as Clinical Study Consultant.
2023
Galibra Neuroscience was founded by Drs Alexander Rotenberg and Henry Lee.
